Lyophilized Glyburide Formulation pH Control Sorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glyburide formulations face challenges such as reduced concentration due to instability, degradation, and sorption to pharmaceutical containers, low solubility in aqueous solutions, and the need for specialized infusion sets, which complicates administration and leads to sub-therapeutic doses.
Innovation Solution
The development of lyophilized formulations comprising glyburide, a base, and a sugar alcohol, configured to be reconstituted with a buffering agent, which maintains a pH outside the buffering capacity of the agent, thereby minimizing sorption and enhancing stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If glyburide is formulated in aqueous solutions at typical pH ranges (pH 5-9), then the formulation can be administered intravenously, but the solubility is extremely low and sorption to containers occurs
Solution Approach 1:
The patent changes the pH parameter from the typical aqueous range (pH 5-9) to a highly alkaline range (pH 10-12), which fundamentally alters the solubility and container interaction properties of glyburide, enabling it to dissolve at meaningful concentrations and resist sorption to polymeric containers
Solution Approach 2:
The patent introduces a buffering agent as an intermediary substance that mediates between the highly alkaline glyburide formulation and the patient's physiological systems. The buffer maintains the alkaline pH necessary for solubility and stability while preventing direct harmful effects, and the buffering agent itself serves as a sorption sink to protect glyburide from binding to containers
2Loss of substance
If specialized low-sorbing infusion sets are used, then glyburide sorption is minimized, but device complexity increases and availability is limited
Solution Approach 1:
The patent converts the potentially harmful interaction between glyburide and polymeric containers into a beneficial relationship by using the alkaline formulation to make glyburide repel sorption sites. The highly alkaline pH creates an electrostatic and chemical environment that actively prevents binding, turning what would be a harmful affinity into a protective repulsion
Solution Approach 2:
The patent enables the glyburide formulation to protect itself from sorption through its inherent chemical properties at high pH. The formulation self-regulates its interaction with containers through the buffering agent, eliminating the need for external protective measures like specialized infusion sets
3Reliability
If glyburide is stored in pharmaceutical containers, then it can be transported and administered, but concentration is reduced due to instability and degradation
Solution Approach 1:
The patent changes the pH parameter to highly alkaline levels (pH 10-12), which fundamentally alters the chemical stability profile of glyburide. At this pH, the drug becomes resistant to degradation pathways that operate at neutral or acidic pH, thereby maintaining concentration and reliability during storage and administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a stable and soluble glyburide formulation with reduced sorption to medical containers, allowing for precise and accurate dosing with minimal impurities and drug waste, while requiring less saline infusion fluid.
Implementation Method 1
configured to be reconstituted with a buffering agent, which maintains a pH outside the buffering capacity of the agent
Implementation Method 2
minimizing sorption to medical containers
Implementation Method 3
enhancing stability and solubility
Data Source
AI summary
The disclosure relates to compositions and methods of using a pomalidomide derivative that exhibits improved pharmacological effects as compared to pomalidomide for treating brain diseases. The pomalidomide derivative exhibits excellent binding to cereblon, has almost no cytotoxicity, is unlikely to cause teratogenic adverse effects, can control TNF-α expression, exhibits excellent in vivo pharmacokinetic stability while suppressing oxidative stress, ameliorates a decrease in motor function which is a symptom of Parkinson's disease, and increases tyrosine hydroxylase expression which is reduced by Parkinson's disease, and thus can be used for preventing or treating brain diseases such as Parkinson's disease.